share_log

Maxim Group Initiates Coverage On Lexaria Bioscience With Buy Rating, Announces Price Target of $2

Maxim Group Initiates Coverage On Lexaria Bioscience With Buy Rating, Announces Price Target of $2

Maxim Group 以买入评级开始对 Lexaria Bioscience 进行报道,宣布目标股价为 2 美元
Benzinga ·  2023/07/21 10:00

Maxim Group analyst Michael Okunewitch initiates coverage on Lexaria Bioscience (NASDAQ:LEXX) with a Buy rating and announces Price Target of $2.

Maxim Group分析师Michael Okunewitch对Lexaria Bioscience(纳斯达克:Lexx)进行了买入评级,并宣布目标价为2美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发